Literature DB >> 6337988

Cefaclor and amoxycillin in the treatment of infective exacerbations of chronic bronchitis.

M R Law, H A Holt, D S Reeves, M E Hodson.   

Abstract

The clinical effectiveness of cefaclor 500 mg three times daily in the treatment of acute infective exacerbations of chronic bronchitis has been investigated by a double-blind comparison with amoxycillin in the same dose in 30 in-patients and 50 out-patients. The two antibiotics were equally effective, in terms of resolution of presenting symptoms, sputum conversion and fall in 24 h sputum weight. Side effects were infrequent. Serum and sputum concentrations of antibiotics and 24 h urinary recovery were measured in 27 patients. Concentration of both cefaclor and amoxycillin was found to be significantly lower in mucoid sputum than in purulent sputum, in contrast to earlier reports in the case of amoxycillin. No clinical advantage was apparent for patients achieving higher sputum concentration of either antibiotic.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6337988     DOI: 10.1093/jac/11.1.83

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Ecology of Haemophilus influenzae and Haemophilus parainfluenzae in sputum and saliva and effects of antibiotics on their distribution in patients with lower respiratory tract infections.

Authors:  J E Foweraker; N J Cooke; P M Hawkey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

2.  Double-blind comparative study of two dosage regimens of cefaclor and amoxicillin-clavulanic acid in the outpatient treatment of soft tissue infections.

Authors:  F D Pien
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

3.  Use of an enzyme-linked immunosorbent assay to assess penetration of amoxicillin into lung secretions.

Authors:  S L Hill; D Burnett; A L Lovering; R A Stockley
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 4.  Epidemiology and treatment of chronic bronchitis and its exacerbations.

Authors:  P Ball
Journal:  Chest       Date:  1995-08       Impact factor: 9.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.